N-3 polyunsaturated fatty acids administration does not reduce the recurrence rates of atrial fibrillation and inflammation after electrical cardioversion: A prospective randomized study;N-3 çoklu doymamış yaǧ asitlerinin kullanımı elektriksel kardiyoversiyon sonrası inflamasyon ve atriyal fibrilasyon nüks oranlarını azaltmaz: Prospektif randomize bir çalışma

Anadolu Kardiyoloji Dergisi

Volumn 11, Issue 4, 2011, Pages 305-309

  Özaydin, Mehmet ^a   Erdoǧan, Doǧan ^a   Tayyar, Şenol ^a   Uysal, Bayram Ali ^a   Doǧan, Abdullah ^a   Içli, Atilla ^a   Özkan, Emel ^b   Varol, Ercan ^a   Türker, Yasin ^b   Arslan, Akif ^a  

^a SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b Gulkent State Hospital   (Turkey)

Author keywords

Atrial fibrillation; Cox proportional regression analysis; Polyunsaturated fatty acids; Recurrence

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCOSAHEXAENOIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; MARINCAP; OMEGA 3 FATTY ACID; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVERSION; CONTROLLED STUDY; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTHYROIDISM; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SINUS RHYTHM; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE;

EID: 79958158125     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: 10.5152/akd.2011.080     Document Type: Article

References (28)

1. Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 2004; 62: 105-111.
2. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104: 2886-2891.
3. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96: 1180-1184.
4. Patti G, Chello M, Candura D, Pasceri V, D'Ambrosio A, Covino E, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 2006; 114: 1455-1461.
5. Özaydin M, Dogan A, Varol E, Kapan S, Tüzün N, Peker O, et al. Statin use before by-pass surgery decreases the incidence and shortens the duration of postoperative atrial fibrillation. Cardiology 2007; 107: 117-121.
6. Marin F, Pascual DA, Roldan V, Arribas JM, Ahumada M, Tornel PL, et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol 2006; 97: 55-60.
7. Young-Xu Y, Jabbour S, Goldberg R, Blatt CM, Graboys T, Bilchik B, et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003; 92: 1379-1383.
8. Hanna IR, Heeke B, Bush H, Brosius L, King-Hageman D, Dudley SC Jr, et al. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 2006; 3: 881-886.
9. Özaydin M, Türker Y, Erdogan D, Karabacak M, Dogan A, Varol E, et al. The association between previous statin use and development of atrial fibrillation in patients presenting with acute coronary syndrome. Int J Cardiol 2010; 141: 147-150.
10. Özaydin M, Varol E, Aslan SM, Küçüktepe Z, Dogan A, Öztürk M, et al. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol 2006; 97: 1490-1493.
11. Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003; 92: 1343-1345.
12. Micallef MA, Garg ML. Anti-inflammatory and cardioprotective effects of n-3 polyunsaturated fatty acids and plant sterols in hyperlipidemic individuals. Atherosclerosis 2008; 204: 476-482.
13. Calo L, Bianconi L, Colivicchi F, Lamberti F, Loricchio ML, de Ruvo E, et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol 2005; 45: 1723-1728.
14. Mozaffarian D, Psaty BM, Rimm EB, Lemaitre RN, Burke GL, Lyles MF, et al. Fish intake and risk of incident atrial fibrillation. Circulation 2004; 110: 368-373.
15. Frost L, Vestergaard P. N-3 Fatty acids consumed from fish and risk of atrial fibrillation or flutter the Danish Diet, Cancer, and Health Study. Am J Clin Nutr 2005; 81: 50-54.
16. Macchia A, Monte S, Pellegrini F, Romero M, Ferrante D, Doval H, et al. Omega-3 fatty acid supplementation reduces one-year risk of atrial fibrillation in patients hospitalized with myocardial infarction. Eur J Clin Pharmacol 2008; 64: 627-634.
17. Boriani G, Diemberger I, Biffi M, Domenichini G, Martignani C, Valzania C, et al. Electrical cardioversion for persistent atrial fibrillation or atrial flutter in clinical practice: predictors of longterm outcome. Int J Clin Pract 2007; 61: 748-756.
18. Kosior DA, Szulc M, Opolski G, Torbicki A, Rabczenko D. Long-term sinus rhythm maintenance after cardioversion of persistent atrial fibrillation: is the treatment's success predictable? Heart Vessels 2006; 21: 375-381.
19. Blich M, Edoute Y. Electrical cardioversion for persistent or chronic atrial fibrillation: outcome and clinical factors predicting short and long-term success rate. Int J Cardiol 2006; 107: 389-394.
20. Ninio DM, Murphy KJ, Howe PR, Saint DA. Dietary fish oil protects against stretch-induced vulnerability to atrial fibrillation in a rabbit model. J Cardiovasc Electrophysiol 2005; 16: 1189-1194.
21. Aizer A, Gaziano JM, Manson JE, Buring JE, Albert CM. Relationship between fish consumption and the development of atrial fibrillation in men. Heart Rhythm 2006; 3: S5.
22. Brouwer IA, Heeringa J, Geleijnse JM. Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation. The Rotterdam Study. Am Heart J 2006; 151: 857-862.
23. Berry JD, Prineas RJ, van Horn L, Passman R, Larson J, Goldberger J, et al. Dietary fish intake and incident atrial fibrillation (from the Women's Health Initiative). Am J Cardiol 2010; 105: 844-848.
24. Erdogan A, Bayer M, Kollath D, Greiss H, Voss R, Neumann T, et al. Omega AF study: polyunsaturated fatty acids (PUFA) for prevention of atrial fibrillation relapse after successful external cardioversion. Heart Rhythm 2007; 4: S185-S186.
25. Savelieva I, Camm J. Statins and polyunsaturated fatty acids for treatment of atrial fibrillation. Nat Clin Pract Cardiovasc Med 2008; 5: 30-41.
26. Li GR, Sun HY, Zhang XH, Cheng LC, Chiu SW, Tse HF, et al. Omega-3 polyunsaturated fatty acids inhibit transient outward and ultrarapid delayed rectifier K+ currents and Na+ current in human atrial myocytes. Cardiovasc Res 2009; 81: 286-293.
27. Pratt CM, Reiffel JA, Ellenbogen KA, Naccarelli GV, Kowey PR. Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: a prospective study. Am Heart J 2009; 158: 163-169.
28. Macchia A, Varini S, Grancelli H, Nul D, Laffaye N, Ferrante D et al. The rationale and design of the FORomegaARD Trial: a randomized, double-blind, placebo-controlled, independent study to test the efficacy of n-3 PUFA for the maintenance of normal sinus rhythm in patients with previous atrial fibrillation. Am Heart J 2009; 157: 423-427.